These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38265568)

  • 1. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
    van de Loo ME; Andour L; van Heesewijk AE; Oosterkamp HM; Liefers GJ; Straver ME
    Breast Cancer Res Treat; 2024 May; 205(1):5-16. PubMed ID: 38265568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Madigan LI; Dinh P; Graham JD
    Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
    Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
    JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
    Huang L; Xu AM
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
    van Olmen JP; Jacobs CF; Bartels SAL; Loo CE; Sanders J; Vrancken Peeters MTFD; Drukker CA; van Duijnhoven FH; Kok M
    Breast; 2024 Jun; 75():103726. PubMed ID: 38599047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
    Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
    Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
    Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
    J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
    Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
    BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis.
    Cui M; Fu J; Li Q
    BMC Cancer; 2024 Oct; 24(1):1293. PubMed ID: 39425072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable outcome of neoadjuvant endocrine treatment than surgery-first in female HR-positive/HER2-negative breast cancer patients-A NCDB analysis (2010-2016).
    Xu P; Luo W; Hu J; Ma X; Hao Q; Hui W; Zhou Z; Lin S; Wang M; Wu H; Dai Z; Kang H
    Cancer Med; 2024 Jun; 13(11):e7244. PubMed ID: 38859692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
    Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
    Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends.
    Graham PJ; Brar MS; Foster T; McCall M; Bouchard-Fortier A; Temple W; Quan ML
    Ann Surg Oncol; 2015 Oct; 22(10):3376-82. PubMed ID: 26202561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of breast cancer in countries with limited resources.
    Carlson RW; Anderson BO; Chopra R; Eniu AE; Jakesz R; Love RR; Masetti R; Schwartsmann G;
    Breast J; 2003; 9 Suppl 2():S67-74. PubMed ID: 12713499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
    Semiglazov VF; Semiglazov VV; Petrenko OL; Komyakhov AV; Dashyan GA; Paltuev RM; Semiglazova TY; Manikhas AG; Bozhok AA; Lalak IA
    Vopr Onkol; 2015; 61(3):381-6. PubMed ID: 26242149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
    Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
    Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.